Market Cap 9.17M
Revenue (ttm) 16.02M
Net Income (ttm) 3.59M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 22.41%
Debt to Equity Ratio 0.00
Volume 29,900
Avg Vol 75,468
Day's Range N/A - N/A
Shares Out 3.43M
Stochastic %K 51%
Beta -0.64
Analysts Strong Sell
Price Target $11.00

Company Profile

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydr...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 224 9600
Address:
332 Encinitas Boulevard, Suite 102, Encinitas, United States
Jake140
Jake140 Aug. 21 at 10:59 AM
0 · Reply
Rafiullah_100
Rafiullah_100 Aug. 19 at 4:45 AM
$KPRX disappointed stock
0 · Reply
Jake140
Jake140 Aug. 18 at 11:26 AM
0 · Reply
StockScanners
StockScanners Aug. 16 at 2:14 AM
$KPRX keep watch if this holds above 2.80
0 · Reply
Raxothus
Raxothus Aug. 15 at 7:21 PM
EOD CONTINUATION WATCHLIST – 08/15/25 Focused on stocks that held VWAP and pushed into Power Hour with strength $CAMP – 3.2x volume, 6.7% VWAP stretch, micro float. 6.5% open-to-current with strong 10.0% late push, RSI 62.7. Needs breakout over 1.69+ for continuation $BNRG – 8.7x volume, 3.6% VWAP stretch, micro float. 16.4% open-to-current with slight -1.7% late pull, RSI 47.3. Needs breakout over 2.39+ for continuation $KPRX – 5.7x volume, 2.9% VWAP stretch, micro float. 14.2% open-to-current with 2.1% late push, RSI 58.8. Needs breakout over 3.01+ for continuation $VTGN – 6.7x volume, 7.2% VWAP stretch, small float. 9.9% open-to-current with slight -0.2% late pull, RSI 46.7. Needs breakout over 3.35+ for continuation $GNSS – 2.6x volume, 3.0% VWAP stretch, small float. 15.2% open-to-current with -0.1% late pull, RSI 52.2. Needs breakout over 1.92+ for continuation #EOD #VWAP #Momentum #SmallCaps #DayTrading #ContinuationSetups #PowerHourWatch
0 · Reply
Shes_Pumping_Mud
Shes_Pumping_Mud Aug. 15 at 5:41 PM
$OPEN sold $KPRX to add more to $OPEN
0 · Reply
Bruceswingsteen
Bruceswingsteen Aug. 15 at 2:22 PM
$KPRX over $3 this goes insane with multiple halts imo
1 · Reply
Bruceswingsteen
Bruceswingsteen Aug. 15 at 2:16 PM
$KPRX took size
0 · Reply
Jake140
Jake140 Aug. 15 at 1:53 PM
$KPRX Nice to see some movement here! I'm still down $$, but holding! Let's go!!!
0 · Reply
Stmkr
Stmkr Aug. 13 at 10:11 AM
$KPRX Trading at half cash. Readout early 2027 so seemingly no short term catalyst. But KIO-104 still unpartnered
0 · Reply
Latest News on KPRX
Bonds still bouncing along

Sep 9, 2024, 4:55 PM EDT - 1 year ago

Bonds still bouncing along

CPLS EYEG HYFI JPST TLT USHY YEAR


AllianceBernstein Launches Five New Active ETFs

Dec 13, 2023, 7:30 AM EST - 1 year ago

AllianceBernstein Launches Five New Active ETFs

AB BUFC CPLS EYEG TAFL TAFM


Jake140
Jake140 Aug. 21 at 10:59 AM
0 · Reply
Rafiullah_100
Rafiullah_100 Aug. 19 at 4:45 AM
$KPRX disappointed stock
0 · Reply
Jake140
Jake140 Aug. 18 at 11:26 AM
0 · Reply
StockScanners
StockScanners Aug. 16 at 2:14 AM
$KPRX keep watch if this holds above 2.80
0 · Reply
Raxothus
Raxothus Aug. 15 at 7:21 PM
EOD CONTINUATION WATCHLIST – 08/15/25 Focused on stocks that held VWAP and pushed into Power Hour with strength $CAMP – 3.2x volume, 6.7% VWAP stretch, micro float. 6.5% open-to-current with strong 10.0% late push, RSI 62.7. Needs breakout over 1.69+ for continuation $BNRG – 8.7x volume, 3.6% VWAP stretch, micro float. 16.4% open-to-current with slight -1.7% late pull, RSI 47.3. Needs breakout over 2.39+ for continuation $KPRX – 5.7x volume, 2.9% VWAP stretch, micro float. 14.2% open-to-current with 2.1% late push, RSI 58.8. Needs breakout over 3.01+ for continuation $VTGN – 6.7x volume, 7.2% VWAP stretch, small float. 9.9% open-to-current with slight -0.2% late pull, RSI 46.7. Needs breakout over 3.35+ for continuation $GNSS – 2.6x volume, 3.0% VWAP stretch, small float. 15.2% open-to-current with -0.1% late pull, RSI 52.2. Needs breakout over 1.92+ for continuation #EOD #VWAP #Momentum #SmallCaps #DayTrading #ContinuationSetups #PowerHourWatch
0 · Reply
Shes_Pumping_Mud
Shes_Pumping_Mud Aug. 15 at 5:41 PM
$OPEN sold $KPRX to add more to $OPEN
0 · Reply
Bruceswingsteen
Bruceswingsteen Aug. 15 at 2:22 PM
$KPRX over $3 this goes insane with multiple halts imo
1 · Reply
Bruceswingsteen
Bruceswingsteen Aug. 15 at 2:16 PM
$KPRX took size
0 · Reply
Jake140
Jake140 Aug. 15 at 1:53 PM
$KPRX Nice to see some movement here! I'm still down $$, but holding! Let's go!!!
0 · Reply
Stmkr
Stmkr Aug. 13 at 10:11 AM
$KPRX Trading at half cash. Readout early 2027 so seemingly no short term catalyst. But KIO-104 still unpartnered
0 · Reply
ExecutiveEdge
ExecutiveEdge Aug. 12 at 11:17 PM
TGL WATCH THIS ONE Crypto treasury plays are starting to run hot and TGL is sitting under $1 with an intrinsic value near $11. Q3 AI + blockchain product reveal, 2.7M+ users, and a micro float already rotated multiple times. This is the kind of setup that can go from quiet to vertical in days. $MLGO $KPRX $WISA $WINT
0 · Reply
Jake140
Jake140 Aug. 12 at 12:39 PM
0 · Reply
Jake140
Jake140 Aug. 10 at 9:53 AM
0 · Reply
Jake140
Jake140 Aug. 8 at 4:43 PM
$KPRX Where is the bottom already??!?
0 · Reply
Stmkr
Stmkr Aug. 8 at 11:56 AM
$KPRX $7.5M market vs 20+M cash and runway into late 2027 through readouts for both ph2 assets. One asset partnered already with decent milestones (relevant to market cap) The other remains available for partnering. Someone explain why this is so undervalued? Lack of obvious short term catalysts is the only "issue" I see
2 · Reply
BigSqueezeComing
BigSqueezeComing Aug. 8 at 11:02 AM
$KPRX Closed the quarter with $20.7 million in cash and equivalents, plus $2.4 million in collaboration receivables and $0.7 million in research tax credits. Estimated runway extends into late 2027.
0 · Reply
BigSqueezeComing
BigSqueezeComing Aug. 8 at 11:02 AM
$KPRX Launched the KLARITY Phase 2 trial targeting retinal inflammatory diseases like posterior non‑infectious uveitis and diabetic macular edema. The asset’s patent life has been secured through 2043, excluding potential extensions. • KIO‑301: Initiated the ABACUS‑2 Phase 2 trial for vision restoration in retinitis pigmentosa patients, using a validated functional vision endpoint that may support future registration studies.
0 · Reply
BigSqueezeComing
BigSqueezeComing Aug. 8 at 11:01 AM
$KPRX https://www.newsfilecorp.com/release/261730/Kiora-Pharmaceuticals-Reports-Second-Quarter-2025-Results-Company-Advances-Pipeline-with-Two-Active-Phase-2-Clinical-Trials-for-Retinal-Diseases
0 · Reply
newsfile_corp
newsfile_corp Aug. 8 at 11:01 AM
https://nfne.ws/261730 $KPRX #Chemicals #Pharmaceutical #Biotechnology #Medical #Pharmaceuticals #Earnings #QuarterlyResults #Results #NASD
0 · Reply
Jake140
Jake140 Jul. 24 at 11:01 AM
$KPRX Patience, patience. Takes time...
1 · Reply
astonm
astonm Jul. 23 at 10:53 AM
0 · Reply
Jake140
Jake140 Jul. 23 at 8:39 AM
0 · Reply